Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994 Jul;35(7):891–895. doi: 10.1136/gut.35.7.891

Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID.

A S Taha 1, S Dahill 1, R D Sturrock 1, F D Lee 1, R I Russell 1
PMCID: PMC1374834  PMID: 8063215

Abstract

Although ulcers are often associated with non-steroidal anti-inflammatory drugs (NSAIDs) little is known about the feasibility of predicting their development in patients taking NSAIDs. In addition, the ulcerogenic potentials of the newer NSAIDs, taken on long term basis, have not been compared with those of more established preparations. The aim of this study was to identify the clinical and pathological characteristics of patients at a higher risk of NSAID induced ulcers, measure the ulcerogenic potential of a variety of NSAIDs, and test the effect of these potentials on the predictability of ulceration. Altogether 190 long term NSAID users were studied. The presence of abdominal complaints, previous history of ulcers, arthritis related physical disability, anaemia, gastritis, and Helicobacter pylori status were all assessed as possible risk factors. NSAIDs were classified into established drugs (group I), and newer agents (group II). Group I included naproxen, indomethacin, diclofenac, ketoprofen, piroxicam, and flurbiprofen. Group II included fenbufen, nabumetone, ibuprofen, etodolac, azapropazone, and tiaprofenic acid. Of 63 ulcers identified in the study group, 51 (81%) were seen in group I NSAID patients (51 of 132, 39%) compared with 12 ulcers in group II (12 of 58, 21%), p < 0.02; estimated relative risk (ERR): 2.41). In group I, 25 ulcers were found in 38 patients with abdominal pain (25 of 38, 66%, p < 0.01, ERR: 5.03); 18 in 25 (72%) patients with a previous history of ulcers (p < 0.001, ERR: 5.77), 26 in 44 (59%) patients with debilitating arthritis (p < 0.001, ERR 3.64), and 35 in 73 (48%) patients with H pylori associated gastritis (p < 0.01, ERR: 2.48). The presence of these factors in group II patients did not influence the risk of ulceration. Group I NSAIDs were more likely to be associated with chemical gastritis and to intensify H pylori related damage. Although silent ulcers are not uncommon in patients taking NSAIDs, recognition of the risk factors might helps predict a significant number (up to 81%), especially in those receiving group I NSAIDs.

Full text

PDF
891

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong C. P., Blower A. L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987 May;28(5):527–532. doi: 10.1136/gut.28.5.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Caruso I., Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. Br Med J. 1980 Jan 12;280(6207):75–78. doi: 10.1136/bmj.280.6207.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collier D. S., Pain J. A. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 1985 Apr;26(4):359–363. doi: 10.1136/gut.26.4.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davenport P. M., Morgan A. G., Darnborough A., De Dombal F. T. Can preliminary screening of dyspeptic patients allow more effective use of investigational techniques? Br Med J (Clin Res Ed) 1985 Jan 19;290(6463):217–220. doi: 10.1136/bmj.290.6463.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dixon M. F., O'Connor H. J., Axon A. T., King R. F., Johnston D. Reflux gastritis: distinct histopathological entity? J Clin Pathol. 1986 May;39(5):524–530. doi: 10.1136/jcp.39.5.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dixon M. F., Wyatt J. I., Burke D. A., Rathbone B. J. Lymphocytic gastritis--relationship to Campylobacter pylori infection. J Pathol. 1988 Feb;154(2):125–132. doi: 10.1002/path.1711540204. [DOI] [PubMed] [Google Scholar]
  7. Ehsanullah R. S., Page M. C., Tildesley G., Wood J. R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988 Oct 22;297(6655):1017–1021. doi: 10.1136/bmj.297.6655.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Graham D. Y. Helicobacter pylori and the endoscopist: whether to diagnose. Gastrointest Endosc. 1991 Sep-Oct;37(5):577–579. doi: 10.1016/s0016-5107(91)70838-9. [DOI] [PubMed] [Google Scholar]
  9. Graham D. Y., Lidsky M. D., Cox A. M., Evans D. J., Jr, Evans D. G., Alpert L., Klein P. D., Sessoms S. L., Michaletz P. A., Saeed Z. A. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991 Jun;100(6):1653–1657. doi: 10.1016/0016-5085(91)90665-8. [DOI] [PubMed] [Google Scholar]
  10. Hallissey M. T., Allum W. H., Jewkes A. J., Ellis D. J., Fielding J. W. Early detection of gastric cancer. BMJ. 1990 Sep 15;301(6751):513–515. doi: 10.1136/bmj.301.6751.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Holdstock G., Harman M., Machin D., Patel C., Lloyd R. S. Prospective testing of a scoring system designed to improve case selection for upper gastrointestinal investigation. Gastroenterology. 1986 May;90(5 Pt 1):1164–1169. doi: 10.1016/0016-5085(86)90381-1. [DOI] [PubMed] [Google Scholar]
  12. Lanza F. L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1989;163:24–31. doi: 10.3109/00365528909091171. [DOI] [PubMed] [Google Scholar]
  13. Loeb D. S., Talley N. J., Ahlquist D. A., Carpenter H. A., Zinsmeister A. R. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology. 1992 Jun;102(6):1899–1905. doi: 10.1016/0016-5085(92)90311-l. [DOI] [PubMed] [Google Scholar]
  14. Mann J., Holdstock G., Harman M., Machin D., Loehry C. A. Scoring system to improve cost effectiveness of open access endoscopy. Br Med J (Clin Res Ed) 1983 Oct 1;287(6397):937–940. doi: 10.1136/bmj.287.6397.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Skander M. P., Ryan F. P. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ. 1988 Oct 1;297(6652):833–834. doi: 10.1136/bmj.297.6652.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sobala G. M., Crabtree J. E., Pentith J. A., Rathbone B. J., Shallcross T. M., Wyatt J. I., Dixon M. F., Heatley R. V., Axon A. T. Screening dyspepsia by serology to Helicobacter pylori. Lancet. 1991 Jul 13;338(8759):94–96. doi: 10.1016/0140-6736(91)90085-4. [DOI] [PubMed] [Google Scholar]
  17. Sobala G. M., King R. F., Axon A. T., Dixon M. F. Reflux gastritis in the intact stomach. J Clin Pathol. 1990 Apr;43(4):303–306. doi: 10.1136/jcp.43.4.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Somerville K., Faulkner G., Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986 Mar 1;1(8479):462–464. doi: 10.1016/s0140-6736(86)92927-2. [DOI] [PubMed] [Google Scholar]
  19. Taha A. S., Angerson W., Nakshabendi I., Beekman H., Morran C., Sturrock R. D., Russell R. I. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs--influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther. 1993 Feb;7(1):41–45. doi: 10.1111/j.1365-2036.1993.tb00067.x. [DOI] [PubMed] [Google Scholar]
  20. Taha A. S., Boothman P., Holland P., McKinlay A., Upadhyay R., Kelly R. W., Lee F., Russell R. I. Gastric mucosal prostaglandin synthesis in the presence of Campylobacter pylori in patients with gastric ulcers and non-ulcer dyspepsia. Am J Gastroenterol. 1990 Jan;85(1):47–50. [PubMed] [Google Scholar]
  21. Taha A. S., McLaughlin S., Holland P. J., Kelly R. W., Sturrock R. D., Russell R. I. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis. 1990 Jun;49(6):354–358. doi: 10.1136/ard.49.6.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Taha A. S., McLaughlin S., Sturrock R. D., Russell R. I. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol. 1989 Aug;28(4):329–332. doi: 10.1093/rheumatology/28.4.329. [DOI] [PubMed] [Google Scholar]
  23. Taha A. S., Morran C., Sturrock R. D., Russell R. I. The Health Assessment Questionnaire as a predictor of non-steroidal peptic ulceration. Br J Rheumatol. 1993 Feb;32(2):135–138. doi: 10.1093/rheumatology/32.2.135. [DOI] [PubMed] [Google Scholar]
  24. Taha A. S., Nakshabendi I., Lee F. D., Sturrock R. D., Russell R. I. Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. J Clin Pathol. 1992 Feb;45(2):135–139. doi: 10.1136/jcp.45.2.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Taha A. S., Reid J., Boothmann P., Gemmell C. G., Lee F. D., Sturrock R. D., Russell R. I. Serological diagnosis of Helicobacter pylori--evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs. Gut. 1993 Apr;34(4):461–465. doi: 10.1136/gut.34.4.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Williams B., Luckas M., Ellingham J. H., Dain A., Wicks A. C. Do young patients with dyspepsia need investigation? Lancet. 1988 Dec 10;2(8624):1349–1351. doi: 10.1016/s0140-6736(88)90879-3. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES